Table of Contents
ISRN Obstetrics and Gynecology
Volume 2011, Article ID 457204, 20 pages
http://dx.doi.org/10.5402/2011/457204
Review Article

Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females

Center of Excellence, Women's Health, University of Missouri-Kansas City School of Medicine, 7900 Lee's Summit Road, Kansas City, MO 64139, USA

Received 6 June 2011; Accepted 13 July 2011

Academic Editor: L. C. Zeferino

Copyright © 2011 Diane M. Harper and Stephen L. Vierthaler. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. H. Schiffman and R. D. Burk, “Human papillomaviruses,” in Viral Infections of Humans: Epidemiology and Control, A. S. Evans and R. A. Daslow, Eds., pp. 983–1023, Plenum Medical Book Company, New York, NY, USA, 4th edition, 1997. View at Google Scholar
  2. H. zur Hausen, “Condylomata acuminata and human genital cancer,” Cancer Research, vol. 36, no. 2 part 2, p. 794, 1976. View at Google Scholar
  3. A. Meisels and R. Fortin, “Condylomatous lesions of the cervix and vagina. I. Cytologic patterns,” Acta Cytologica, vol. 20, no. 6, pp. 505–509, 1976. View at Google Scholar
  4. E. L. Franco and D. M. Harper, “Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control,” Vaccine, vol. 23, no. 17-18, pp. 2388–2394, 2005. View at Publisher · View at Google Scholar · View at PubMed
  5. N. Muñoz, F. X. Bosch, S de Sanjosé et al., “Epidemiologic classification of human papillomavirus types associated with cervical cancer,” The New England Journal of Medicine, vol. 348, no. 6, pp. 518–527, 2003. View at Google Scholar
  6. V. Bouvard, R. Baan, K. Straif et al., “A review of human carcinogens—part B: biological agents,” The Lancet oncology, vol. 10, no. 4, pp. 321–322, 2009. View at Google Scholar
  7. M. J. Khan, P. E. Castle, A. T. Lorincz et al., “The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice,” Journal of the National Cancer Institute, vol. 97, no. 14, pp. 1072–1079, 2005. View at Publisher · View at Google Scholar · View at PubMed
  8. J. R. Arrand, “Molecular genetics of human papillomaviruses,” in Human Papillomaviruses and Cervical Cancer: Biology and Immunology, P. L. Stern and M. A. Stanley, Eds., chapter 2, pp. 28–37, Oxford University Press, New York, NY, USA, 1994. View at Google Scholar
  9. M. Schiffman and A. C. Rodríguez, “Heterogeneity in CIN3 diagnosis,” The Lancet Oncology, vol. 9, no. 5, pp. 404–406, 2008. View at Publisher · View at Google Scholar · View at PubMed
  10. M. R. McCredie, K. J. Sharples, C. Paul et al., “Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study,” The Lancet Oncology, vol. 9, no. 5, pp. 425–434, 2008. View at Publisher · View at Google Scholar · View at PubMed
  11. A. G. Ostör, “Natural history of cervical intraepithelial neoplasia: a critical review,” International Journal of Gynecological Pathology, vol. 12, no. 2, pp. 186–192, 1993. View at Google Scholar
  12. P. E. Castle, M. Schiffman, C. M. Wheeler, N. Wentzensen, and P. E. Gravitt, “Impact of improved classification on the association of human papillomavirus with cervical precancer,” The American Journal of Epidemiology, vol. 171, no. 2, pp. 155–163, 2010. View at Publisher · View at Google Scholar · View at PubMed
  13. J. D. Carreon, M. E. Sherman, D. Guillén et al., “CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples,” International Journal of Gynecological Pathology, vol. 26, no. 4, pp. 441–446, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. A. B. Moscicki, Y. Ma, C. Wibbelsman et al., “Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women,” Obstetrics and Gynecology, vol. 116, no. 6, pp. 1373–1380, 2010. View at Google Scholar
  15. W. Y. Zhang, Y. Z. Xue, M. Chen, L. Han, and M. Luo, “Prevalence of high-risk human papillomavirus infection in different cervical lesion among organized health-examination women in Shanghai, China,” Chinese Medical Journal, vol. 121, no. 16, pp. 1578–1582, 2008. View at Google Scholar
  16. K. Cuschieri and N. Wentzensen, “Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 10, pp. 2536–2545, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. H. Trottier, S. M. Mahmud, L. Lindsay et al., “Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women,” Cancer Epidemiology, Biomarkers & Prevention, vol. 18, no. 3, pp. 854–62, 2009. View at Google Scholar
  18. P. E. Castle, S. Wacholder, A. T. Lorincz et al., “A prospective study of high-grade cervical neoplasia risk among human papillomavirus infected women,” Journal of the National Cancer Institute, vol. 94, no. 18, pp. 1406–1414, 2002. View at Google Scholar
  19. V. Dalstein, D. Riethmuller, J. L. Préteti et al., “Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study,” International Journal of Cancer, vol. 106, no. 3, pp. 396–403, 2003. View at Publisher · View at Google Scholar · View at PubMed
  20. L. Bruni, M. Diaz, X. Castellsagué, E. Ferrer, F. X. Bosch, and S. De Sanjosé, “Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings,” Journal of Infectious Diseases, vol. 202, no. 12, pp. 1789–1799, 2010. View at Publisher · View at Google Scholar · View at PubMed
  21. H. C. Kitchener, M. Almonte, C. Thomson et al., “HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial,” The Lancet Oncology, vol. 10, no. 7, pp. 672–682, 2009. View at Publisher · View at Google Scholar
  22. Silvia de Sanjosé, M. Diaz, X. Castellsagué et al., “Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis,” The Lancet Infectious Diseases, vol. 7, pp. 453–459, 2007. View at Google Scholar
  23. G. M. Eversole, A. T. Moriarty, M. R. Schwartz et al., “Practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology, 2006,” Archives of Pathology and Laboratory Medicine, vol. 134, no. 3, pp. 331–335, 2010. View at Google Scholar
  24. H. Trottier, S. Mahmud, J. C. M. Prado et al., “Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination,” Journal of Infectious Diseases, vol. 197, no. 10, pp. 1436–1447, 2008. View at Publisher · View at Google Scholar · View at PubMed
  25. Finnish Cancer Registry, http://www.cancerregistry.fi/stats/eng/veng0006i0.html.
  26. G. Y. Ho, Y. Y. Studentsov, R. Bierman, and R. D. Burk, “Natural history of human papillomavirus type 16 virus-like particle antibodies in young women,” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 1, pp. 110–116, 2004. View at Publisher · View at Google Scholar
  27. C. Porras, C. Bennett, M. Safaeian et al., “Determinants of seropositivity among HPV 16/18 DNA positive young women,” BMC Infectious Diseases, vol. 10, p. 238, 2010. View at Google Scholar
  28. S. Coseo, C. Porras, A. Hildesheim et al., “Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica,” Sexually Transmitted Diseases, vol. 37, no. 11, pp. 706–714, 2010. View at Publisher · View at Google Scholar · View at PubMed
  29. J. J. Carter, L. A. Koutsky, J. P. Hughes et al., “Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection,” Journal of Infectious Diseases, vol. 181, no. 6, pp. 1911–1919, 2000. View at Publisher · View at Google Scholar · View at PubMed
  30. S. E. Olsson, S. K. Kjaer, K. Sigurdsson et al., “Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection,” Human Vaccines, vol. 5, no. 10, pp. 696–704, 2009. View at Publisher · View at Google Scholar
  31. M. Safaeian, C. Porras, M. Schiffman et al., “Epidemiological study of Anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections,” Journal of the National Cancer Institute, vol. 102, no. 21, pp. 1653–1662, 2010. View at Publisher · View at Google Scholar · View at PubMed
  32. R. P. Viscidi, M. Schiffman, A. Hildesheim et al., “Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica,” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 2, pp. 324–327, 2004. View at Publisher · View at Google Scholar
  33. M. Stanley, “Immune responses to human papillomavirus,” Vaccine, vol. 24, supplement 1, pp. S16–S22, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. H. A. Cubie, M. Plumstead, W. Zhang, O. De Jesus, L. A. Duncan, and M. A. Stanley, “Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11-13-year-old schoolgirls,” Journal of Medical Virology, vol. 56, no. 3, pp. 210–216, 1998. View at Publisher · View at Google Scholar
  35. E. F. Dunne, K. L. Karem, M. R. Sternberg et al., “Seroprevalence of human papillomavirus type 16 in children,” Journal of Infectious Diseases, vol. 191, no. 11, pp. 1817–1819, 2005. View at Publisher · View at Google Scholar · View at PubMed
  36. M. A. Rintala, S. E. Grénman, M. E. Järvenkylä, K. J. Syrjänen, and S. M. Syrjänen, “High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study,” Clinical Infectious Diseases, vol. 41, no. 12, pp. 1728–1733, 2005. View at Publisher · View at Google Scholar · View at PubMed
  37. P. S. Rice, J. Cason, J. M. Best, and J. E. Banatvala, “High risk genital papillomavirus infections are spread vertically,” Reviews in Medical Virology, vol. 9, no. 1, pp. 15–21, 1999. View at Publisher · View at Google Scholar
  38. X. Castellsagué, T. Drudis, M. P. Cañadas et al., “Human Papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain,” BMC Infectious Diseases, vol. 9, article 74, 2009. View at Publisher · View at Google Scholar · View at PubMed
  39. M. A. Rintala, S. E. Grénman, M. H. Puranen et al., “Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland,” Journal of Clinical Microbiology, vol. 43, no. 1, pp. 376–381, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. N. Muñoz, F. Méndez, H. Posso et al., “Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results,” Journal of Infectious Diseases, vol. 190, no. 12, pp. 2077–2087, 2004. View at Google Scholar
  41. J. W. Sellors, T. L. Karwalajtys, J. Kaczorowski et al., “Incidence, clearance and predictors of human papillomavirus infection in women,” The Canadian Medical Association Journal, vol. 168, no. 4, pp. 421–425, 2003. View at Google Scholar
  42. E. L. Franco, L. L. Villa, J. P. Sobrinho et al., “Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer,” Journal of Infectious Diseases, vol. 180, no. 5, pp. 1415–1423, 1999. View at Publisher · View at Google Scholar · View at PubMed
  43. M. J. Grainge, R. Seth, L. Guo et al., “Cervical human papillomavirus screening among older women,” Emerging Infectious Diseases, vol. 11, no. 11, pp. 1680–1685, 2005. View at Google Scholar
  44. X. Castellsagué, A. Schneider, A. M. Kaufmann, and F. X. Bosch, “HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives,” Gynecologic Oncology, vol. 115, no. 3, pp. S15–S23, 2009. View at Google Scholar
  45. A. C. Rodriguez, M. Schiffman, R. Herrero et al., “Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection,” Journal of the National Cancer Institute, vol. 102, no. 5, pp. 1–10, 2010. View at Publisher · View at Google Scholar · View at PubMed
  46. P. Gonzalez, A. Hildesheim, A. C. Rodriguez et al., “Behavioral/lifestyle and immunological factors associated with HPV infection among women older than 45 years of age,” Cancer Epidemiology, Biomarkers & Prevention, vol. 19, p. 3044, 2010. View at Publisher · View at Google Scholar · View at PubMed
  47. C. Porras, A. C. Rodríguez, A. Hildesheim et al., “Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 3, pp. 863–865, 2009. View at Publisher · View at Google Scholar · View at PubMed
  48. F. X. Bosch and S. de Sanjosé, “Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality,” Journal of the National Cancer Institute. Monographs, no. 31, pp. 3–13, 2003. View at Google Scholar
  49. H. Trottier, S. Ferreira, P. Thomann et al., “Human papillomavirus infection and re-infection in adult women: the role of sexual activity and natural immunity,” Cancer Research, vol. 70, no. 21, pp. 8569–8577, 2010. View at Publisher · View at Google Scholar · View at PubMed
  50. G. Edgren and P. Sparén, “Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study,” The Lancet Oncology, vol. 8, no. 4, pp. 311–316, 2007. View at Publisher · View at Google Scholar · View at PubMed
  51. I. Kalliala, A. Anttila, E. Pukkala, and P. Nieminen, “Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study,” The British Medical Journal, vol. 331, no. 7526, pp. 1183–1185, 2005. View at Publisher · View at Google Scholar · View at PubMed
  52. B. Strander, A. Andersson-Ellström, I. Milsom, and P. Sparén, “Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study,” The British Medical Journal, vol. 335, no. 7629, pp. 1077–1080, 2007. View at Publisher · View at Google Scholar · View at PubMed
  53. P. P. Martin-Hirsch, E. Paraskevaidis, A. Bryant, H. O. Dickinson, and S. L. Keep, “Surgery for cervical intraepithelial neoplasia,” Cochrane Database of Systematic Reviews, vol. 6, p. CD001318, 2010. View at Google Scholar
  54. S. Ghaem-Maghami, S. Sagi, G. Majeed, and W. P. Soutter, “Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis,” The Lancet Oncology, vol. 8, no. 11, pp. 985–993, 2007. View at Publisher · View at Google Scholar · View at PubMed
  55. E. F. Dunne, E. R. Unger, M. Sternberg et al., “Prevalence of HPV infection among females in the United States,” Journal of the American Medical Association, vol. 297, no. 8, pp. 813–819, 2007. View at Publisher · View at Google Scholar · View at PubMed
  56. FUTURE II Study Group, “Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions,” The New England Journal of Medicine, vol. 356, no. 19, pp. 1915–1927, 2007. View at Google Scholar
  57. J. Paavonen, P. Naud, J. Salmerón et al., “Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women,” The Lancet, vol. 374, no. 9686, pp. 301–314, 2009. View at Publisher · View at Google Scholar
  58. G. M. Clifford, R. K. Rana, S. Franceschi, J. S. Smith, G. Gough, and J. M. Pimenta, “Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 5, pp. 1157–1164, 2005. View at Publisher · View at Google Scholar · View at PubMed
  59. G. M. Clifford, J. S. Smith, T. Aguado, and S. Franceschi, “Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis,” The British Journal of Cancer, vol. 89, no. 1, pp. 101–105, 2003. View at Publisher · View at Google Scholar · View at PubMed
  60. S. de Sanjose, W. G. V. Quint, L. Alemany et al., “Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study,” The Lancet Oncology, vol. 11, no. 11, pp. 1048–1056, 2010. View at Publisher · View at Google Scholar
  61. X. Castellsagué, M. Díaz, S. de Sanjosé et al., “Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention,” Journal of the National Cancer Institute, vol. 98, no. 5, pp. 303–315, 2006. View at Google Scholar
  62. G. M. Clifford, S. Gallus, R. Herrero et al., “Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis,” The Lancet, vol. 366, no. 9490, pp. 991–998, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. S. L. Giannini, E. Hanon, P. Moris et al., “Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only,” Vaccine, vol. 24, no. 33-34, pp. 5937–5949, 2006. View at Publisher · View at Google Scholar · View at PubMed
  64. N. De Carvalho, J. Teixeira, C. M. Roteli-Martins et al., “Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women,” Vaccine, vol. 28, no. 38, pp. 6247–6255, 2010. View at Publisher · View at Google Scholar · View at PubMed
  65. The GlaxoSmithKline Vaccine HPV-023 Study Group, “Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 8.4 years,” in Proceedings of the European Society Paediatric Infectious Disease Conference, (ESPID), abstract 632, May 2010.
  66. C. M. Wheeler et al., “Cross-protective efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: end-of-study (4-year) analysis of the randomised, double-blind PATRICIA trials,” Lancet Oncology. In press.
  67. A. Szarewski, W. Poppe, S. Skinner et al., “Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18.,” International Journal of Cancer. In press. View at Publisher · View at Google Scholar · View at PubMed
  68. A. R. Kreimer, A. C. Rodriguez, A. Hildesheim et al., “Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine,” Journal of the National Cancer Institute, vol. 103, no. 19, pp. 1444–1451, 2011. View at Google Scholar
  69. D. M. Harper, E. L. Franco, C. Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” The Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar · View at PubMed
  70. D. M. Harper, E. L. Franco, C. M. Wheeler et al., “Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial,” The Lancet, vol. 367, no. 9518, pp. 1247–1255, 2006. View at Publisher · View at Google Scholar · View at PubMed
  71. T. F. Schwarz, M. Spaczynski, A. Schneider et al., “Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years,” Vaccine, vol. 27, pp. 581–587, 2009. View at Google Scholar
  72. C. Pedersen, T. Petaja, G. Strauss et al., “Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant,” Journal of Adolescent Health, vol. 40, no. 6, pp. 564–571, 2007. View at Publisher · View at Google Scholar · View at PubMed
  73. M. Schiffman, “Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing,” Cancer, vol. 111, no. 3, pp. 145–153, 2007. View at Publisher · View at Google Scholar · View at PubMed
  74. J. Berkhof, J. Bogaards, V. Coupé, and C. J. M. Meijer, “Modelling the influence of screening uptake on the future incidence of cervical cancer and the cost-effectiveness of HPV vaccination,” in Proceedings of the 26th International Papillomavirus Conference, Montreal, Canada, July 2010.
  75. D. M. Harper, P. Nieminen, J. Paavonen, and M. Lehtinen, “Cervical cancer incidence can increase despite HPV vaccination,” The Lancet Infectious Diseases, vol. 10, no. 9, pp. 594–595, 2010. View at Publisher · View at Google Scholar
  76. R. V. Barnabas, P. Laukkanen, P. Koskela, O. Kontula, M. Lehtinen, and G. P. Garnett, “Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses,” PLoS Medicine, vol. 3, no. 5, p. e138, 2006. View at Publisher · View at Google Scholar · View at PubMed
  77. D. M. Parkin, “The global health burden of infection-associated cancers in the year 2002,” International Journal of Cancer, vol. 118, no. 12, pp. 3030–3044, 2006. View at Publisher · View at Google Scholar · View at PubMed
  78. E. R. Myers, “The economic impact of HPV vaccines: not just cervical cancer,” The American Journal of Obstetrics and Gynecology, vol. 198, no. 5, pp. 487–488, 2008. View at Publisher · View at Google Scholar · View at PubMed
  79. G. M. Ginsberg, T. T. Edejer, J. A. Lauer, and C. Sepulveda, “Screening, prevention and treatment of cervical cancer—a global and regional generalized cost-effectiveness analysis,” Vaccine, vol. 27, no. 43, pp. 6060–6079, 2009. View at Publisher · View at Google Scholar · View at PubMed
  80. J. J. Kim and S. J. Goldie, “Health and economic implications of HPV vaccination in the United States,” The New England Journal of Medicine, vol. 359, no. 8, pp. 821–832, 2008. View at Publisher · View at Google Scholar · View at PubMed
  81. J. J. Kim, M. Brisson, W. J. Edmunds, and S. J. Goldie, “Modeling cervical cancer prevention in developed countries,” Vaccine, vol. 26, no. 10, pp. K76–K86, 2008. View at Publisher · View at Google Scholar · View at PubMed
  82. H. W. Chesson, D. U. Ekwueme, M. Saraiya, and L. E. Markowitz, “Cost-effectiveness of human papillomavirus vaccination in the United States,” Emerging Infectious Diseases, vol. 14, no. 2, pp. 244–251, 2008. View at Google Scholar
  83. World Health Organization, “WHO/ICO (Institut Català d'Oncologia) information centre on HPV and cervical cancer,” http://www.who.int/hpvcentre/en/.
  84. “Globocan 2008,” http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900.
  85. G. Vanagas, Z. Padaiga, J. Kurtinaitis, and Z. Logminiene, “Cost-effectiveness of 12- and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania,” Scandinavian Journal of Public Health, vol. 38, no. 6, pp. 639–647, 2010. View at Publisher · View at Google Scholar · View at PubMed
  86. R. P. Insinga, A. G. Glass, and B. B. Rush, “Diagnoses and outcomes in cervical cancer screening: a population-based study,” The American Journal of Obstetrics and Gynecology, vol. 191, no. 1, pp. 105–113, 2004. View at Publisher · View at Google Scholar · View at PubMed
  87. S. L. Kulasingam, S. Pagliusi, and E. Myers, “Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S,” Vaccine, vol. 25, no. 48, pp. 8110–8113, 2007. View at Publisher · View at Google Scholar · View at PubMed
  88. M. Brisson, N. Van De Velde, and M. C. Boily, “Economic evaluation of human papillomavirus vaccination in developed countries,” Public Health Genomics, vol. 12, no. 5-6, pp. 343–351, 2009. View at Publisher · View at Google Scholar · View at PubMed
  89. I. Zechmeister, B. F. D. Blasio, G. Garnett, A. R. Neilson, and U. Siebert, “Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria,” Vaccine, vol. 27, no. 37, pp. 5133–5141, 2009. View at Publisher · View at Google Scholar · View at PubMed
  90. M. Jit, Y. H. Choi, and W. J. Edmunds, “Economic evaluation of human papillomavirus vaccination in the United Kingdom,” The British Medical Journal, vol. 337, p. a769, 2008. View at Publisher · View at Google Scholar
  91. V. M. H. Coupe, J. van Ginkel, H. E. de Melker, P. J. F. Snijders, C. J. L. M. Meijer, and J. Berkhof, “HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness,” International Journal of Cancer, vol. 124, no. 4, pp. 970–978, 2009. View at Publisher · View at Google Scholar · View at PubMed
  92. I. M. C. M. de Kok, M. van Ballegooijen, and J. D. F. Habbema, “Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands,” Journal of the National Cancer Institute, vol. 101, no. 15, pp. 1083–1092, 2009. View at Publisher · View at Google Scholar · View at PubMed
  93. S. J. Goldie, M. Diaz, D. Constenla, N. Alvis, J. K. Andrus, and S. Y. Kim, “Mathematical models of cervical cancer prevention in Latin America and the Caribbean,” Vaccine, vol. 26, no. 11, pp. L59–L72, 2008. View at Publisher · View at Google Scholar · View at PubMed
  94. J. J. Kim, K. E. Kobus, M. Diaz, M. O'Shea, H. Van Minh, and S. J. Goldie, “Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy,” Vaccine, vol. 26, no. 32, pp. 4015–4024, 2008. View at Publisher · View at Google Scholar · View at PubMed
  95. M. Diaz, J. J. Kim, G. Albero et al., “Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India,” The British Journal of Cancer, vol. 99, no. 2, pp. 230–238, 2008. View at Publisher · View at Google Scholar · View at PubMed
  96. N. Van de Velde, M. Brisson, and M. C. Boily, “Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty,” The American Journal of Epidemiology, vol. 165, no. 7, pp. 762–775, 2007. View at Publisher · View at Google Scholar · View at PubMed
  97. J. J. Kim, K. E. Kobus, M. Diaz, M. O'Shea, H. Van Minh, and S. J. Goldie, “Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy,” Vaccine, vol. 26, no. 32, pp. 4015–4024, 2008. View at Publisher · View at Google Scholar · View at PubMed
  98. G. P. Garnett, J. J. Kim, K. French, and S. J. Goldie, “Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes,” Vaccine, vol. 24, supplement 3, pp. 178–186, 2006. View at Publisher · View at Google Scholar · View at PubMed
  99. M. Brisson, N. Van de Velde, P. De Wals, and M. C. Boily, “The potential cost effectiveness of prophylactic human papillomavirus vaccines in Canada,” Vaccine, vol. 25, no. 29, pp. 5399–5408, 2007. View at Publisher · View at Google Scholar · View at PubMed
  100. K. Oddsson, J. Johannsson, T. L. Asgeirsdottir, and T. Gudnason, “Cost-effectiveness of human papilloma virus vaccination in Iceland,” Acta Obstetricia et Gynecologica Scandinavica, vol. 88, no. 12, pp. 1411–1416, 2009. View at Google Scholar
  101. D. M. Harper, S. L. Vierthaler, and J. A. Santee, “Review of Gardasil,” J Vaccin Vaccinat, vol. 1, p. 107, 2010. View at Publisher · View at Google Scholar
  102. D. M. Harper and K. B. Williams, “Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies,” Discovery Medicine, vol. 10, pp. 7–17, 2010. View at Google Scholar
  103. L. Lancucki, M. Fender, A. Koukari et al., “A fall-off in cervical screening coverage of younger women in developed countries,” Journal of Medical Screening, vol. 17, no. 2, pp. 91–96, 2010. View at Publisher · View at Google Scholar · View at PubMed
  104. A. M. Didierlaurent, S. Morel, L. Lockman et al., “AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity,” Journal of Immunology, vol. 183, no. 10, pp. 6186–6197, 2009. View at Publisher · View at Google Scholar · View at PubMed
  105. N. Garcon, M. Van Mechelen, and M. Wettendorff, “Development and evaluation of AS04, a novel and improved adjuvant system containing PL and aluminium salt,” in Immunopotentiators in Modern Vaccines, V. E. J. C. Schijns and D. T. O'Hagan, Eds., pp. 161–177, Elsevier Academic Press, London, UK, 2006. View at Google Scholar
  106. S. Thoelen, N. De Clercq, and N. Tornieporth, “A prophylactic hepatitis B vaccine with a novel adjuvant system,” Vaccine, vol. 19, no. 17–19, pp. 2400–2403, 2001. View at Publisher · View at Google Scholar
  107. N. K. Tong, J. Beran, S. A. Kee et al., “Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients,” Kidney International, vol. 68, no. 5, pp. 2298–2303, 2005. View at Publisher · View at Google Scholar · View at PubMed
  108. G. Boland, J. Beran, M. Lievens et al., “Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with As04,” Vaccine, vol. 23, no. 3, pp. 316–320, 2004. View at Publisher · View at Google Scholar · View at PubMed
  109. Cervarix Package Insert, GlaxoSmithKline Biologicals, Rixensart, Belgium, 2009.
  110. D. Le Tallec, D. Doucet, A. Elouahabi, P. Harvengt, M. Deschuyteneer, and M. Deschamps, “Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions,” Human Vaccines, vol. 5, no. 7, pp. 467–474, 2009. View at Google Scholar
  111. S. R. Pagliusi and M. T. Aguado, “Efficacy and other milestones for human papillomavirus vaccine introduction,” Vaccine, vol. 23, no. 5, pp. 569–578, 2004. View at Publisher · View at Google Scholar
  112. “Follow-up study to evaluate the long-term efficacy of a HPV vaccine in healthy young adult women in Brazil,” Human Papillomavirus Types 16 And 18 Vaccine, 109616 (HPV-023 EXT 001 Y7), 109624 (HPV-023 EXT 001 Y8), http://download.gsk-clinicalstudyregister.com/files/20207.pdf.
  113. H. O. Smith, M. F. Tiffany, C. R. Qualls, and C. R. Key, “The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study,” Gynecologic Oncology, vol. 78, no. 2, pp. 97–105, 2000. View at Publisher · View at Google Scholar · View at PubMed
  114. M. Lehtinen et al., “Overall efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia grade 3 or greater: end-of-study analysis of the randomised, double-blind PATRICIA trial,” Lancet Oncology. In press.
  115. M. Schiffman, M. Safaeian, and N. Wentzensen, “The use of human papillomavirus seroepidemiology to inform vaccine policy,” Sexually Transmitted Diseases, vol. 36, no. 11, pp. 675–679, 2009. View at Publisher · View at Google Scholar · View at PubMed
  116. E. M. Smith, M. A. Parker, L. M. Rubenstein, T. H. Haugen, E. Hamsikova, and LP Turek, “Evidence for vertical transmission of HPV from mothers to infants,” Infectious Diseases in Obstetrics and Gynecology, vol. 2010, Article ID 326369, 7 pages, 2010. View at Publisher · View at Google Scholar · View at PubMed
  117. “National, state, and local area vaccination coverage among adolescents aged 13–17 years—United States,” Morbidity and Mortality Weekly Report, Centers for Disease Control and Prevention, 2009, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5932a3.htm?s_cid=mm5932a3_w.
  118. M. Arbyn, C. Simoens, P. Van Damme, A. Scharpantgen, C. J. Meijer, and P. Beutels, “Introduction of human papillomavirus vaccination in Belgium, Luxembourg and the Netherlands,” Gynecologic and Obstetric Investigation, vol. 70, no. 4, pp. 224–232, 2010. View at Google Scholar
  119. http://www.cdc.gov/vaccines/stats-surv/nhis/downloads/2009-nhis-tables.xls.
  120. T. F. Schwarz, L. M. Huang, D. M. Rivera Medina et al., “4-Year follow up of immunogenicity and safety of adolescent girls vaccinated with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine,” in Proceedings of the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Nice, France, May 2010.
  121. A. Hildesheim, R. Herrero, S. Wacholder et al., “Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial,” Journal of the American Medical Association, vol. 298, no. 7, pp. 743–753, 2007. View at Publisher · View at Google Scholar · View at PubMed
  122. S. K. Pacher, H. E. Rosenthal, H. Perlitz et al., “Direct Longitudinal comparison over 12 month of T cell responses to prophylactic HPV vaccines,” in Proceedings of the 26th International Papillomavirus Conference, Montreal, Canada, July 2010.
  123. M. H. Einstein and HPV-010 Study Group, “Immunogenicity comparison of two prophylactic human papillomavirus cervical cancer vaccines at month 36,” in Proceedings of the European Research Organisation in Genital Infection and Neoplasia (EuroGin), presentation SS-19-3, Lisbon, Portugal, February 2011.
  124. K. Soldan, R. Howell-Jones, G. Leong, G. Hughes, and O. N. Gill, “Immunisation causing declines in genital warts in England,” in the 27th IPV Conference OP-32.04, Berlin, Germany, September 18–22, 2011.
  125. P. Naud, C. M. Roteli-Martins, N. De Carvalho et al., “Sustained immunogenicity and efficacy up to 9.4 years,” in Proceedings of the 27th International Papillomavirus Conference, Abstract O-18.04, Berlin, Germany, Septebmer 2011.
  126. F. Dessy, S. Poncelet, V. Xhenseval, D. Méric, G. Dubin, and HPV-010 Study Group, “Comparative evaluation of the immunogenicity of two prophylactic HPV cervical cancer vaccines by Merck's competitive Luminex immunoassay (cLIA) and GSK's binding ELISA,” in Proceedings of the European Research Organisation in Genital Infection and Neoplasia, (EuroGin), presentation P IM-5, Monte Carlo, Monaco, February 2009.
  127. J. T. Schiller and P. Davies, “Delivering on the promise: HPV vaccines and cervical cancer,” Nature Reviews Microbiology, vol. 2, no. 4, pp. 343–347, 2004. View at Publisher · View at Google Scholar · View at PubMed
  128. D. Nardelli-Haefliger, D. Wirthner, J. T. Schiller et al., “Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles,” Journal of the National Cancer Institute, vol. 95, no. 15, pp. 1128–1137, 2003. View at Google Scholar
  129. J. Paavonen, D. Jenkins, F. X. Bosch et al., “Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial,” The Lancet, vol. 369, no. 9580, pp. 2161–2170, 2007. View at Publisher · View at Google Scholar · View at PubMed
  130. D. M. Harper, “Primary prevention of HPV-associated diseases,” Public Health Genomics, vol. 12, no. 5-6, pp. 319–330, 2009. View at Publisher · View at Google Scholar · View at PubMed
  131. T. F. Schwarz, M. Spaczynski, A. Schneider et al., “Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 years,” Hum Vaccin, vol. 7, no. 9, pp. 958–965, 2011. View at Google Scholar
  132. T. Petaja, H. Keränen, T. Karppa et al., “Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years,” Journal of Adolescent Health, vol. 44, no. 1, pp. 33–40, 2009. View at Publisher · View at Google Scholar · View at PubMed
  133. J. Garcia-Sicilia, T. F. Schwarz, A. Carmona et al., “Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine co-administered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women,” Journal of Adolescent Health, vol. 46, no. 2, pp. 142–151, 2010. View at Google Scholar
  134. V. Schaffer, S. Wimmer, I. Rotaru, R. Topakian, H. P. Haring, and F. T. Aichner, “HPV Vaccine: a cornerstone of female health- a possible cause of ADEM?” Journal of Neurology, vol. 255, pp. 1818–1820, 2008. View at Google Scholar
  135. B. Romanowski, T. Schwarz, L. Ferguson et al., “HPV-16/18 AS04-adjuvanted vaccine administered as a 2 dose schedule compared with the standard 3 dose schedule,” in Proceedings of the European Research Organisation in Genital Infection and Neoplasia, (EuroGin), abstract SS 11-5, Monte Carlo, Monaco, 2010.
  136. http://www.medscape.com/viewarticle/559807.
  137. http://clinicaltrials.gov/ct2/results?term=Cervarix&pg=2/.
  138. S. Keam and D. M. Harper, “Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]: profile report,” BioDrugs, vol. 22, no. 3, pp. 205–208, 2008. View at Publisher · View at Google Scholar
  139. A. Szarewski, E. Lazcano, S. Angsuwathana et al., “Safety of human papillomavirus (HPV) 16/18 AS04 cervical cancer vaccine candidate in women aged 26 years or older. The HPV VIVIANE study group,” in Proceedings of the European Research Organisation in Genital Infection and Neoplasia, (EuroGin), abstract SS2-4, Monte Carlo, Monaco, October 2007.
  140. D. Descamps, K. Hardt, B. Spiessens et al., “Safety of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials,” Human Vaccines, vol. 5, no. 5, pp. 332–340, 2009. View at Publisher · View at Google Scholar
  141. S. Wacholder, B. E. Chen, A. Wilcox et al., “Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized controlled trials,” The British Medical Journal, vol. 340, p. c712, 2010. View at Publisher · View at Google Scholar
  142. “Cervarix pregnancy registry registration form,” http://pregnancyregistry.gsk.com/documents/cervarix_pregnancy_registry_registration_form.pdf.
  143. World Health Organization, “Adverse Events Following Immunization (AEFI): causality assessment,” http://whqlibdoc.who.int/aide-memoire/a87773_eng.pdf.
  144. J. Gee, A. Naleway, I. Shui, and B. Slade, “Post-licensure safety monitoring of human papillomavirus(HPV) vaccines,” 2010, http://www.cdc.gov/vaccinesafety/vaccines/hpv/gardasil.html. View at Google Scholar
  145. “FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP),” Morbidity and Mortality Weekly Report, 2010, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm/.
  146. “Highlights of prescribing information,” http://us.gsk.com/products/assets/us_cervarix.pdf.
  147. M. Arbyn, P. Autier, and J. Ferlay, “Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004,” Annals of Oncology, vol. 18, no. 8, pp. 1423–1425, 2007. View at Publisher · View at Google Scholar · View at PubMed
  148. “United States cancer statistics,” 2007, http://apps.nccd.cdc.gov/uscs/cancersbyraceandethnicity.aspx/.
  149. J. Colgrove, S. Abiola, and M. M. Mello, “HPV vaccination mandates—lawmaking amid political and scientific controversy,” The New England Journal of Medicine, vol. 363, no. 8, pp. 785–791, 2010. View at Publisher · View at Google Scholar · View at PubMed
  150. D. M. Harper and J. Paavonen, “Age for HPV vaccination,” Vaccine, vol. 26, no. 1, pp. A7–A11, 2008. View at Publisher · View at Google Scholar
  151. X. Castellsagué, A. Schneider, A. M. Kaufmann, and F. X. Bosch, “HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives,” Gynecologic Oncology, vol. 115, no. 3, pp. S15–S23, 2009. View at Google Scholar
  152. D. M. Parkin and F. Bray, “Chapter 2. The burden of HPV-related cancers,” Vaccine, vol. 24, no. 3, pp. S11–S25, 2006. View at Publisher · View at Google Scholar · View at PubMed
  153. A. R. Kreimer, P. González, H. A. Katki et al., “Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica vaccine trial,” Lancet Oncology, vol. 12, no. 9, pp. 862–870, 2011. View at Google Scholar
  154. M. Lehtinen, D. Apter, G. Dubin et al., “Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing,” International Journal of STD & AIDS, vol. 17, no. 8, pp. 517–521, 2006. View at Publisher · View at Google Scholar · View at PubMed
  155. S. M. Garland on behalf of the HPV-008 study group, “VIN/VaIN1+ data associated with HPV-16/18 for the TVC, TVC-naive and ATP-E cohorts,” in Proceedings of the 27th International Papillomavirus Conference, OP-32.03, Berlin, Germany, Septebmer 2011.